MetabolicFDA Approved

Semaglutide (Ozempic/Wegovy)

Subcutaneous injection (weekly), Oral (daily - Rybelsus)

Overview

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite.

Mechanism of Action

Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days..

Research Summary & Key Findings

STEP trials demonstrated ~15% mean body weight reduction. SELECT trial (2023) showed 20% reduction in major adverse cardiovascular events in overweight/obese adults without diabetes. FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy).

Clinical Status

FDA Approved

Semaglutide (Ozempic/Wegovy) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (weekly)Oral (daily - Rybelsus)

Related Peptides in Metabolic

Find a Provider

Find a verified provider who offers Semaglutide (Ozempic/Wegovy) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Semaglutide (Ozempic/Wegovy).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.